(BFM Stock Exchange) – The company specializing in assembly and components for aeronautics, the automobile and the medical climb on the Paris Stock Exchange after announcing the entry into exclusive negotiations with SK Capital to sell Lisi Medical. This would allow society to reduce debt and refocus it on its core business.

Small fever of fever on Lisi on the stock market. The action of the company specializing in assembly solutions and structures for aeronautics (58% of its revenues), the automobile (32%) and the medical, takes 5.9% around 4 p.m.

This increase is due to the announcement of the company communicated Wednesday evening. Lisi said that he had entered into exclusive negotiations with private investor SK Capital to give him his Lisi Medical division, specializing in the subcontracting of medical devices (orthopedic implants, surgery instruments).

This division achieved a turnover of 185 million euros in 2024 and has 857 employees.

>> Access our exclusive graphic analyzes, and enter into the confidence of the trading portfolio

An operation with multiple virtues

As part of this transfer, the amount of which has not been communicated, Lisi would take a 10% stake in the capital of the SK Capital holding company which will buy Lisi Medical. This in order to be associated “with the planned transformation project” for its subsidiary, explains the group.

The two parties expect the transaction to be finalized during the second half of 2025. In a note, TP ICAP Midcap believes that this operation would prove to be beneficial for Lisi with several titles.

First of all, the design office estimates that a 90% transfer of Lisi Medical titles could bring around 335 million euros in cash, allowing it to reduce its net debt, which amounted to 488 million euros to the end of 2024.

This debt is limited to the group’s room for maneuver, both in terms of mergers and acquisitions policy and return to the shareholder (dividends, share buyers). Lisi had notably spent, in 2023, more than 200 million euros to buy 14% of his own shares following a recomposition of his shareholding.

TP ICAP also believes that this sale will allow Lisi to focus “a little more the group on its aeronautical activity” and “will simplify its history” stock market.

The design office also stresses that the moment of the announcement of this sale falls out.

The project of sale “intervenes while the division has entered the harvesting phase since 2022 and achieves the best margins of the group, which should result in a high valuation retained by SK Capital”, explains TP ICAP Midcap. “In addition, holding 10% of the control holding company will allow Lisi to expose themselves to the appreciation potential of the Medical Division”, concludes the design office.